{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:16:50Z","timestamp":1791238610349,"version":"4.1.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p><jats:bold>Aim:<\/jats:bold> The aim of this study is to determine the efficacy and safety of the combination therapy of drug-eluting bead bronchial arterial chemoembolization plus anlotinib oral administration in the treatment of non-small-cell lung cancer (NSCLC).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Consecutive data from 51 patients with advanced NSCLC were retrospectively collected from February 2018 to August 2019. All patients underwent drug-eluting bead bronchial arterial chemoembolization (DEB-BACE) followed by anlotinib treatment. Overall survival (OS) and progression-free survival (PFS) were calculated and analyzed using the Kaplan\u2013Meier method and log-rank test, and factors associated with OS and PFS were assessed by a Cox proportional hazards test. Treatment response at 30 days was assessed by enhanced computed tomography (CT), and then the objective response rate (ORR) and disease control rate (DCR) were calculated. Treatment-related adverse events (TRAEs) were also evaluated.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The median OS was 18.4 months (95% CI, 16.6\u201320.2 months), and the median PFS was 8.4 months (95% CI, 6.2\u201310.6 months). The ORR and DCR for the whole cohort were 21.6 and 100%, respectively, at 30 days after the first cycle of treatment. Most of the treatment-related adverse reactions were mild and moderate and included anorexia, hypertension, fatigue, and hand-foot syndrome. Only eight (15.7%) patients developed grade 3 TRAEs. No deaths or other serious adverse reactions occurred. Both TNM stage and brain metastasis were independent risk factors for OS and PFS.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> DEB-BACE concomitant with anlotinib has promising efficacy and tolerable toxicity in patients with advanced NSCLC.<\/jats:p>","DOI":"10.3389\/fcell.2021.768943","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T06:21:55Z","timestamp":1635488515000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and Safety of Drug-Eluting Bead Bronchial Arterial Chemoembolization Plus Anlotinib in Patients With Advanced Non-small-Cell Lung Cancer"],"prefix":"10.3389","volume":"9","author":[{"given":"Juanfang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenguang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhuang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanguo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1111\/1759-7714.13139","article-title":"The efficacy of drug-eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non-small cell lung cancer.","volume":"10","author":"Bie","year":"2019","journal-title":"Thorac. Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s11547-016-0629-2","article-title":"Transcatheter arterial chemical infusion for advanced non-small-cell lung cancer: long-term outcome and predictor of survival.","volume":"121","author":"Fu","year":"2016","journal-title":"Radiol. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial.","volume":"4","author":"Han","year":"2018","journal-title":"JAMA Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1120009X.2021.1906036","article-title":"Anlotinib as a post-third-line therapy for the treatment of advanced nonsmall cell lung cancer.","author":"Li","year":"2021","journal-title":"J. Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"6239","DOI":"10.2147\/CMAR.S310115","article-title":"Drug-eluting beads bronchial arterial chemoembolization in treating relapsed\/refractory small cell lung cancer patients: results from a pilot study.","volume":"13","author":"Lin","year":"2021","journal-title":"Cancer Manage. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.acra.2019.07.003","article-title":"Safety and efficacy of drug-eluting bead transarterial chemoembolization combined with apatinib in patients with advanced hepatocellular carcinoma.","volume":"27","author":"Liu","year":"2019","journal-title":"Acad. Radiol."},{"key":"B8","first-page":"2554","article-title":"Drug-eluting bead bronchial arterial chemoembolization vs. chemotherapy in treating advanced non-small cell lung cancer: comparison of treatment efficacy, safety and quality of life.","volume":"25","author":"Liu","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111493","article-title":"A small molecular multi-targeting tyrosine kinase inhibitor, anlotinib, inhibits pathological ocular neovascularization.","volume":"138","author":"Lu","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","article-title":"Cancer treatment and survivorship statistics, 2016.","volume":"66","author":"Miller","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1002\/cam4.3941","article-title":"Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.","volume":"10","author":"Qin","year":"2021","journal-title":"Cancer Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"753","DOI":"10.20892\/j.issn.2095-3941.2020.0024","article-title":"Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling.","volume":"17","author":"Qin","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-282608\/v1","article-title":"The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer.","author":"Wang","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.2147\/CMAR.S249678","article-title":"A trial of the safety and efficacy of chemotherapy plus anlotinib vs. chemotherapy alone as second- or third-line salvage treatment for advanced non-small cell lung cancer.","volume":"12","author":"Wang","year":"2020","journal-title":"Cancer Manage. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/1759-7714.13120","article-title":"Salvage treatment with anlotinib for advanced non-small cell lung cancer.","volume":"10","author":"Wu","year":"2019","journal-title":"Thorac. Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025709","article-title":"Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China: a systemic review and meta-analysis of its efficacy and safety.","volume":"100","author":"Ye","year":"2021","journal-title":"Medicine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.jvir.2020.06.007","article-title":"Combination of bronchial arterial infusion chemotherapy plus drug-eluting embolic transarterial chemoembolization for treatment of advanced lung cancer-a retrospective analysis of 23 patients.","volume":"31","author":"Zeng","year":"2020","journal-title":"J. Vasc. Interv. Radiol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022128","article-title":"First-line pemetrexed and carboplatin plus anlotinib for epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative lung adenocarcinoma with brain metastasis: a case report and review of the literature.","volume":"99","author":"Zhang","year":"2020","journal-title":"Medicine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.2147\/CMAR.S246000","article-title":"Efficacy and safety of anlotinib in advanced non-small cell lung cancer: a real-world study.","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancer Manage. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.2147\/CMAR.S304838","article-title":"Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer: a real-world study.","volume":"13","author":"Zhong","year":"2021","journal-title":"Cancer Manage. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.21037\/jtd-20-2855","article-title":"Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer.","volume":"12","author":"Zhong","year":"2020","journal-title":"J. Thorac. Dis."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001186","article-title":"Clinical analysis of anlotinib as first-line treatment for elderly patients with advanced lung adenocarcinoma without driver gene mutations.","author":"Zhu","year":"2021","journal-title":"Anticancer Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/1753465817717169","article-title":"Neoadjuvant chemotherapy by bronchial arterial infusion in patients with unresectable stage III squamous cell lung cancer.","volume":"11","author":"Zhu","year":"2017","journal-title":"Ther. Adv. Respir. Dis."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2021.768943\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T06:21:57Z","timestamp":1635488517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2021.768943\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":23,"alternative-id":["10.3389\/fcell.2021.768943"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2021.768943","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]},"article-number":"768943"}}